Termination of License Rights. Customer’s license rights to the Software shall immediately cease upon termination of the license rights granted to the Customer under the Agreement.
Termination of License Rights. Upon termination of this Agreement for any reason with respect to all Licensed Gene Targets or with respect to all Licensed Products, the Agreement shall be terminated in its entirety and all license rights granted under Section 2.1 shall terminate immediately and automatically upon the effective date of such termination. Upon any termination of this Agreement in part on a Licensed Gene Target-by-Licensed Gene Target basis or a Licensed Product by Licensed Product basis under any of the provisions of this Article 10 (except for a termination under Section 10.2.2, for which the license termination consequences shall be as stated in Section 10.2.2), all license rights granted under Section 2.1 with respect to each such terminated Licensed Gene Target and each related Licensed Product for each such terminated Licensed Gene Target will terminate immediately and automatically upon the effective date of such termination.
Termination of License Rights. Unless and until the Non-Developing Party decides to Opt-in pursuant to the Opt In Trigger described herein, it shall have no further rights under the licenses provided to it under Article 11 with respect to such Independent Product or Independent Indication. *Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.
Termination of License Rights. The License Rights may be terminated in the following circumstances, and upon the effective date of any such termination Genzyme’s right to practice under the License Rights shall cease:
Termination of License Rights. Upon termination of this Agreement for any reason with respect to all Licensed Products, the Agreement shall be terminated in its entirety and all license rights granted under Section 2.1 shall terminate immediately and automatically upon the effective date of such termination.
Termination of License Rights. Upon any termination of Commercial Member’s membership in the Consortium for any reason, this Agreement and all rights granted to Commercial Member hereunder will immediately terminate. In the event that this Agreement is terminated, Commercial Member and its Resellers shall withdraw all inventories of the IntelliCAD Licensed Materials or any Member Application within ninety (90) days from the effective date of termination (the “Transition Period”). Any inventory remaining after the Transition Period must be destroyed at the Commercial Member’s sole cost. All IntelliCAD Base Software and ArchT Software source files must be destroyed immediately upon termination at the Commercial Member’s sole cost and Commercial Member shall certify such destruction to the Consortium within ten (10) days of the effective date of termination.
Termination of License Rights. Seller may terminate the rights granted under this Agreement in Article 3 in the event of (i) a material breach of the provisions of Article 3 which remains uncorrected sixty (60) days after written notice from the Seller specifying that such a breach has occurred and describing it, or (ii) consummation of an action before a court of competent jurisdiction alleging infringement of third party patents claiming the Bt Toxins or a use of such Bt Toxins.
Termination of License Rights. In the event any Product supplied hereunder shall no longer be a Licensed Product under the License Agreement or Pfizer's license with respect thereto under the License Agreement is no longer in effect, then Pfizer's obligations to purchase and XOMA's obligation to supply such Product hereunder shall terminate.
Termination of License Rights. All licenses granted to Licensee hereunder shall terminate immediately upon such termination, except to the extent necessary for Licensee to exercise its obligation under Section 16.5.3, if applicable.
Termination of License Rights. After the Research Program Term, at such time as BMS provides timely notice to Tranzyme in a timely manner that it is no longer actively pursuing any Collaboration Lead as part of a BMS Discovery & Development Program for a Collaboration Target, all Collaboration Leads against such terminated Collaboration Target shall no longer be within the scope of this Agreement, including the licenses granted in Article 5. BMS shall use reasonable efforts to provide notice to Tranzyme of any such occurrence. PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS.
